OncoGenex Says Will Amend Prostate Cancer Trial

by Rajashri on  June 25, 2009 at 7:15 PM Corporate News
RSS Email Print This Page Comment
 OncoGenex Says Will Amend Prostate Cancer Trial
OncoGenex Pharmaceuticals Inc has announced that it has reached an agreement with regulators in the US to amend its late-stage prostate cancer trial. The agreement to amend the trial was reached through the special protocol assessment (SPA) process.
Advertisement

The U.S. Food and Drug Administration said that it agreed to modify the study population in the trial. Initially the trial was monitoring the success of second-line of chemotherapy drugs, but the focus will now be on the first line of drugs.

Advertisement
Last August, OncoGenex merged with Sonus Pharmaceuticals Inc and went public. Versant Partners analyst Douglas Loe said the recommendation was to buy OncoGenex shares as FDA participation bodes well for the company. "I would be comfortable saying that partnership interest would intensify materially on recent regulatory development," he added.

OncoGenex shares were trading up by 17 percent at $22.80 on Nasdaq.



Source: Medindia
RAS
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Prostate Cancer Cancer and Homeopathy Trans-Urethral Resection of the Prostate Prostate Cancer Facts Cancer Facts Cancer Tattoos A Body Art Hematuria Prostate Cancer: Treatment Options Prostate Specific Antigen [PSA] 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive